Loading
institutionsInstitution
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola
Bologna's university hospital, home of the Seràgnoli haematology institute and a leading Italian centre for myeloma, lymphoma and CAR-T.
Also called: Sant'Orsola-MalpighiPoliclinico Sant'OrsolaIstituto di Ematologia Seràgnoli
Overview
The Policlinico Sant'Orsola is the university hospital of the world's oldest university and an IRCCS for transplant and oncology. Its Seràgnoli Institute of Haematology, associated with Michele Cavo (myeloma), Pier Luigi Zinzani (lymphoma) and the GIMEMA cooperative group, has run pivotal Italian trials in myeloma transplantation and lymphoma and is one of Italy's principal CAR-T and allogeneic transplant centres. Medical oncology under Andrea Ardizzoni is active in thoracic and gastrointestinal trials, and the hospital has large paediatric oncology, surgical oncology and nuclear medicine departments. The Emilia-Romagna regional network links it with IRST Meldola.
Location
Bologna, IT
Type
hospital · Università di Bologna
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#205 · 28 points (0 Newsweek + 0 NCI + 28 from 14 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, including child institutions. 229 works · 2,386 citations · 59% open access · 8% clinical trials · 5% reviews.
Oncology works per year
702022
422023
442024
462025
272026
Most works
- Riccardo Casadei28 works
- Lorenzo Fuccio20 works
- Carlo Ingaldi16 works
- Cesare Hassan15 works
- Claudio Ricci15 works
- Marc G. Besselink15 works
- Emi Dika14 works
- Leonardo Frazzoni14 works
- Bergþór Björnsson14 works
- Alessandro Esposito14 works
Most cited
- Seràgnoli haematology institute
- Myeloma and lymphoma trials (GIMEMA)
- CAR-T and transplantation
- Thoracic oncology
- Paediatric oncology
Similar pages
- CompanyPoseida Therapeutics
Shares BCMA, Allogeneic (off-the-shelf) cell therapy, CD20, CAR-T cell therapy.
- IdeaPlan the second CAR-T target before the first one is lost
Shares BCMA, Allogeneic (off-the-shelf) cell therapy, CD20, CAR-T cell therapy.
- InstitutionComprehensive Cancer Center Mainfranken, University Hospital Würzburg
Shares Teclistamab, BCMA, Bispecific antibodies, CAR-T cell therapy.
- PersonPolina Stepensky
Shares BCMA, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Multiple myeloma.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
- InstitutionSeoul St. Mary's Hospital
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia, Multiple myeloma.
- PersonMichael Dickinson
Shares Glofitamab, CD20, Bispecific antibodies, Diffuse large B-cell lymphoma.
- TechnologyNK cell therapy and CAR-NK
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
cancers
fronts
technologies
targets
drugs
ApprovedBispecific T-cell engager (CD20×CD3, 2:1)
Glofitamab · Columvi
ApprovedBispecific T-cell engager (BCMA×CD3)
Teclistamab · Tecvayli